Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 3/20 | 0.41 |
| ▸ | F13A1 | P00488 | 2/20 | 0.41 |
| ▸ | TGM1 | P22735 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923566 | 1.00 | BRD4 (0.46) | BRD4CCR5ALDH1A1KCNA3TGM2 | |
| SCHEMBL23940019 | 0.94 | BRD4 (0.46) | BRD4CCR5ALDH1A1KCNA3TGM2 | |
| SCHEMBL13189171 | 0.79 | USP2 (0.54) | BRD4CCR5ALDH1A1ALOX5APFEN1 | |
| SCHEMBL4703823 | 0.78 | MEN1 (0.63) | CCR5ALDH1A1KCNA3KMT2AMEN1 | |
| SCHEMBL7721392 | 0.76 | BRD4 (0.54) | BRD4CCR5ALDH1A1TGM2F13A1 | |
| SCHEMBL7698054 | 0.76 | BRD4 (0.54) | BRD4CCR5ALDH1A1TGM2F13A1 | |
| SCHEMBL126353 | 0.76 | CCR5 (0.48) | BRD4CCR5ALDH1A1KCNA3TGM2 | |
| SCHEMBL5915338 | 0.74 | MEN1 (0.53) | BRD4TGM2F13A1TGM1KMT2A | |
| SCHEMBL17304702 | 0.74 | KMT2A (0.49) | BRD4CCR5ALDH1A1KCNA3TGM2 | |
| SCHEMBL15932411 | 0.74 | BRD4 (0.56) | BRD4CCR5ALDH1A1KCNA3ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139301-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214080-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | BRD4 2937/4885CCR5 64/4885ALDH1A1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.